4.7 Review

A Test in Context: D-Dimer

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 70, Issue 19, Pages 2411-2420

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.09.024

Keywords

D-dimer; deep-vein thrombosis; disseminated intravascular coagulation; pulmonary embolism; venous thromboembolism

Funding

  1. Bayer
  2. Boehringer Ingelheim
  3. Bristol-Myers Squibb/Pfizer
  4. Daiichi-Sankyo
  5. Janssen
  6. Sanofi
  7. GlaxoSmithKline

Ask authors/readers for more resources

D-dimer is a soluble fibrin degradation product that results from ordered breakdown of thrombi by the fibrinolytic system. Numerous studies have shown that D-dimer serves as a valuable marker of activation of coagulation and fibrinolysis. Consequently, D-dimer has been extensively investigated for the diagnosis of venous thromboembolism (VTE) and is used routinely for this indication. In addition, D-dimer has been evaluated for determining the optimal duration of anticoagulation in VTE patients, for diagnosing and monitoring disseminated intravascular coagulation, and as an aid in the identification of medical patients at high risk for VTE. Thus, quantification of D-dimer levels serves an important role in guiding therapy. This review: 1) describes how D-dimer is generated; 2) reviews the assays used for its detection; and 3) discusses the role of D-dimer determination in these various conditions. Crown Copyright (C) 2017 Published by Elsevier on behalf of the American College of Cardiology Foundation. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available